Drug Profile


Alternative Names: Alisrythm; DU 6552; Pilsinic; Pilzicainide; Rizmsat; Rizumcote; SUN 1165; SUN 1165i; Sunrhythm; Sunrythm; Tatsupilljin

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma
  • Developer Asubio Pharma; Daiichi Sankyo Company
  • Class 2 ring heterocyclic compounds; Acetanilides; Class Ic antiarrhythmics; Pyrrolidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arrhythmias

Most Recent Events

  • 31 Dec 2007 Launched for Arrhythmias in South Korea (PO)
  • 31 Dec 2007 Registered for Arrhythmias in South Korea (PO)
  • 01 Apr 2007 Daiichi Asubio Pharma is now called Asubio Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top